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mpact of Diabetes Mellitus on the
reatment Effect of Percutaneous or
urgical Revascularization for Patients With
nprotected Left Main Coronary Artery Disease
Subgroup Analysis of the MAIN-COMPARE Study
on-Jang Kim, MD, PHD,* Duk-Woo Park, MD, PHD,* Sung-Cheol Yun, PHD,†
ong-Young Lee, MD,* Seung-Whan Lee, MD, PHD,* Young-Hak Kim, MD, PHD,*
heol Whan Lee, MD, PHD,* Seong-Wook Park, MD, PHD,* Seung-Jung Park, MD, PHD*
eoul, Korea
bjectives This study sought to investigate whether the outcome of drug-eluting stent (DES) treat-
ent and that of coronary artery bypass grafting (CABG) differed in diabetic and nondiabetic pa-
ients with unprotected left main coronary artery (LMCA) disease.
ackground Diabetes mellitus has been shown to be a risk factor for adverse events and a major
eterminant in selection of a revascularization strategy in patients with multivessel or LMCA disease.
ethods A total of 1,474 patients with unprotected LMCA stenosis who received DES (n  784) or
nderwent CABG (n  690) were examined. We compared the effects of these 2 treatments on
ong-term clinical outcomes (death; the composite of death, Q-wave myocardial infarction [MI], or
troke; and target vessel revascularization [TVR]), according to diabetic status.
esults After adjustment of covariates, the risk of death (hazard ratio [HR]: 0.95, 95% conﬁdence inter-
al [CI]: 0.62 to 1.46, p  0.83) and the composite of death, Q-wave MI, or stroke (HR: 0.96, 95% CI: 0.65
o 1.42, p  0.85) at 3 years were similar in the DES and CABG groups. However, the rate of TVR was
igniﬁcantly higher in the DES group (HR: 4.31, 95% CI: 2.28 to 8.15, p  0.001). These trends were con-
istent in both diabetic and nondiabetic patients. We also did not observe a diabetes-associated excess
isk of death (pinteraction  0.90 and 0.16), or a composite of death, Q-wave MI, or stroke (pinteraction 
.68 and 0.93), or TVR (pinteraction  0.23 and 0.92), between patients receiving either treatment.
onclusions The prognostic impact of diabetes on long-term treatment with DES or CABG for pa-
ients with unprotected LMCA disease was minimal. (J Am Coll Cardiol Intv 2009;2:956–63) © 2009
y the American College of Cardiology Foundation
rom the *Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; and †Division
f Biostatistics, Center for Medical Research and Information, University of Ulsan College of Medicine, Seoul, Korea. This study
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957atients with diabetes are prone to a diffuse and rapidly
rogressive form of coronary artery disease (1,2). Together
ith coronary artery bypass grafting (CABG), percutaneous
oronary intervention (PCI) is an important component of
evascularization strategy for diabetic patients with signifi-
ant coronary artery disease (3,4). Percutaneous or surgical
evascularization, however, has been associated with higher
ates of short- or long-term complications in diabetic but
ot in nondiabetic patients (5–8).
See page 964
Previous studies have found that surgical revasculariza-
ion resulted in better outcomes than percutaneous revascu-
arization in diabetic patients with multivessel coronary
isease (9), indicating that diabetic status is a major con-
ideration in selection of a revascularization strategy in
atients with multivessel disease. Although the impact of
iabetes on treatment outcomes may be helpful in deter-
ining risk stratification and selecting an optimal strategy,
he prognostic role of diabetes on CABG or PCI outcome
n patients with unprotected left main coronary artery
LMCA) disease has not yet been determined. We therefore
valuated whether the outcome of PCI with drug-eluting
tents (DES) or CABG in patients with unprotected
MCA disease was dependent on diabetic status.
ethods
tudy population and procedures. The study population
onsisted of 1,474 consecutive patients with unprotected
MCA disease (defined as stenosis 50%) who received
ES implantation (n  784) or underwent CABG (n 
90) between May 2003 and June 2006 at 12 major
cademic institutions in Korea, within the MAIN-
OMPARE (revascularization for unprotected left MAIN
oronary artery stenosis: COMparison of Percutaneous
oronary Angioplasty versus surgical REvascularization)
egistry (10). Patients with prior bypass surgery, concomi-
ant valvular or aortic surgery, ST-segment myocardial
nfarction (MI), or cardiogenic shock were excluded.
Patients underwent PCI, rather than CABG, according
o the preference of the patient or physician, taking into
onsideration the high risk associated with CABG (10).
tarting in the second quarter of 2003, DES implantation
as been the exclusive treatment for LMCA disease in all
articipating centers. The choice of sirolimus- (Cypher and
ypher Select, Cordis, Johnson & Johnson, Bridgewater,
ew Jersey) or paclitaxel- (Taxus Express and Liberté,
oston Scientific, Natick, Massachusetts) eluting stents was
t the discretion of the physician. Stent implantation tech-
iques for patients with LMCA disease have been described
10,11). Interventions for any other significant coronary
rtery disease were performed according to current practice ruidelines. All patients receiving DES were prescribed
spirin (200 mg) plus clopidogrel 75 mg (after a loading
ose of 300 or 600 mg) before or during the coronary
ntervention. After the procedure, aspirin was continued
ndefinitely and clopidogrel continued for at least 6 months
12). Extended use of clopidogrel beyond 6 months was at
he discretion of the physician. Surgical revascularization
as performed using standard bypass techniques (13).
henever possible, the internal thoracic artery was prefer-
ntially used for revascularization of the left anterior de-
cending artery.
This study was approved by the ethics committees of each
ospital, which also permitted use of clinical data for this
tudy.
tudy end points and deﬁnitions. The end points of the
tudy were death; the composite of death, Q-wave MI, or
troke; and target vessel revascularization (TVR). All events
ere based on clinical diagnosis by individual physicians and
ere centrally adjudicated by an
ndependent group of clinicians
t the University of Ulsan Col-
ege of Medicine, Asan Medical
enter, Seoul, Korea.
Death was defined as death
rom any cause. Q-wave MI was
efined as documentation of a
ew abnormal Q-wave on elec-
rocardiography and creatine
inase-MB levels 3 the up-
er limit of normal after the
ndex treatment. Stroke, as indi-
ated by neurologic deficits, was
onfirmed by a neurologist based
n imaging studies. TVR was
efined as repeat revasculariza-
ion of the treated vessel, includ-
ng any segments of the left anterior descending artery and
he left circumflex artery (14). The diabetic subgroup was
efined as all patients receiving active treatment with oral
ypoglycemic agents or insulin. Diet-controlled diabetic
atients were included only if there was documentation of
n abnormal blood glucose level after an overnight fast or an
bnormal glucose tolerance test during hospitalization for
he revascularization procedure.
ata collection and follow-up. The MAIN-COMPARE
egistry holds data on all consecutive patients who under-
ent PCI or CABG for unprotected LMCA disease from
000 to 2006 at 12 major cardiac centers (10). The registry
s sponsored by the Korean Society of Interventional Car-
iology, and there was no industry involvement in the
esign, conduct, or analysis of this study.
Clinical, angiographic, procedural or operative, and out-
ome data were collected using a dedicated internet-based
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
IPTW  inverse probability
of treatment weighting
LMCA  left main coronary
artery
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TVR  target vessel
revascularizationeporting system. For validation of complete follow-up data,
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958Table 1. Baseline Clinical and Procedural Characteristics
Overall (n  1,474) Diabetic Patients (n  507) Nondiabetic Patients (n  967)
Variable
DES
(n  784)
CABG
(n  690) p Value
DES
(n  251)
CABG
(n  256) p Value
DES
(n  533)
CABG
(n  434) p Value
Age (yrs) 64 (55–71) 66 (58–70) 0.004 64 (57–71) 66 (59–70) 0.37 63 (52–70) 65 (57–71) 0.006
Male sex 556 (70.9) 499 (72.3) 0.55 174 (69.3) 191 (74.6) 0.19 382 (71.7) 308 (71.0) 0.81
Treatment of diabetes mellitus 0.002 0.006 —
Insulin-requiring 64 (8.2) 68 (9.9) 64 (25.5) 68 (26.6) — —
Oral hypoglycemic agents-requiring 160 (20.4) 179 (25.9) 160 (63.7) 179 (69.9) — —
Diet-controlled 27 (3.4) 9 (1.3) 27 (10.8) 9 (3.5) — —
Hypertension 418 (53.3) 343 (49.7) 0.17 160 (63.7) 153 (59.8) 0.36 258 (48.4) 190 (43.8) 0.15
Hyperlipidemia 241 (30.7) 254 (36.8) 0.014 87 (34.7) 108 (42.2) 0.082 154 (28.9) 146 (33.6) 0.11
Current smoker 166 (21.2) 21.9 (151) 0.74 44 (17.5) 59 (23.0) 0.12 122 (22.9) 92 (21.2) 0.53
Previous coronary angioplasty 160 (20.4) 79 (11.4) 0.001 64 (25.5) 31 (12.1) 0.001 96 (18.0) 48 (11.1) 0.003
Previous myocardial infarction 63 (8.0) 75 (10.9) 0.062 23 (9.2) 35 (13.7) 0.11 40 (7.5) 40 (9.2) 0.34
Previous congestive heart failure 20 (2.6) 22 (3.2) 0.46 11 (4.4) 17 (6.6) 0.27 9 (1.7) 5 (1.2) 0.49
Chronic obstructive pulmonary disease 20 (2.6) 18 (2.6) 0.94 5 (2.0) 4 (1.6) 0.75 15 (2.8) 14 (3.2) 0.71
Cerebrovascular disease 64 (8.2) 47 (6.8) 0.33 26 (10.4) 23 (9.0) 0.60 38 (7.1) 24 (5.5) 0.31
Peripheral vascular disease 14 (1.8) 31 (4.5) 0.003 4 (1.6) 17 (6.6) 0.004 10 (1.9) 14 (3.2) 0.18
Renal failure 26 (3.3) 24 (3.5) 0.86 16 (6.4) 19 (7.4) 0.64 10 (1.9) 5 (1.2) 0.37
Ejection fraction (%) 61 (56–67) 66 (58–70) 0.001 60 (54–66) 58 (45–64) 0.002 62 (57–72) 60 (52–64) 0.001
EuroSCORE 3.0 (2.0–5.0) 4.0 (3.0–6.0) 0.001 4.0 (2.0–6.0) 5.0 (3.0–6.0) 0.001 3.0 (2.0–5.0) 4.0 (3.0–6.0) 0.001
Electrocardiographic ﬁndings 0.67 0.62 0.77
Sinus rhythm 764 (97.4) 667 (96.7) 243 (96.8) 244 (95.3) 521 (97.7) 423 (97.5)
Atrial ﬁbrillation 18 (2.3) 21 (3.0) 6 (2.4) 10 (3.9) 12 (2.3) 11 (2.5)
Other 2 (0.3) 2 (0.3) 2 (0.8) 2 (0.8) 0 0
Clinical indication 0.001 0.001 0.002
Silent ischemia 27 (3.4) 13 (1.9) 11 (4.4) 5 (2.0) 16 (3.0) 8 (1.8)
Chronic stable angina 267 (34.1) 156 (22.6) 78 (31.1) 46 (18.0) 189 (35.5) 110 (25.3)
Unstable angina 405 (51.7) 448 (64.9) 124 (49.4) 171 (66.8) 281 (52.7) 277 (63.8)
NSTEMI 85 (10.8) 73 (10.6) 38 (15.1) 34 (13.3) 47 (8.8) 39 (9.0)
Involved location 0.001 0.001 0.001
Ostium and/or midshaft 336 (42.9) 346 (50.1) 101 (40.2) 125 (48.8) 235 (44.1) 221 (50.9)
Distal bifurcation 448 (57.1) 344 (49.9) 150 (59.8) 131 (51.2) 298 (55.9) 213 (49.1)
Bifurcation lesion classiﬁcation 0.001 0.001 0.001
Isolated distal left main 145 (18.5) 20 (2.9) 49 (19.5) 6 (2.3) 96 (18.0) 14 (3.2)
Distal LM  LAD os or LCX os 180 (22.9) 61 (8.8) 61 (24.3) 22 (8.6) 119 (22.3) 39 (9.0)
Distal LM  LAD os and LCX os 123 (15.7) 263 (38.1) 40 (15.9) 103 (40.2) 83 (15.6) 160 (36.9)
Extent of diseased vessel 0.001 0.001 0.001
LM only 145 (18.5) 26 (3.8) 34 (13.5) 6 (2.3) 111 (20.8) 20 (4.6)
LM plus single-vessel disease 182 (23.2) 54 (7.8) 50 (19.9) 14 (5.5) 132 (24.8) 40 (9.2)
LM plus double-vessel disease 217 (27.7) 160 (23.2) 85 (33.9) 45 (17.6) 132 (24.8) 115 (26.5)
LM plus triple-vessel disease 240 (30.6) 450 (65.2) 82 (32.7) 191 (74.6) 158 (29.6) 259 (59.7)
Right coronary artery disease 333 (42.5) 538 (78.0) 0.001 114 (45.4) 212 (82.8) 0.001 219 (41.1) 326 (75.1) 0.001
Restenotic lesion 27 (3.4) 6 (0.9) 0.001 9 (3.6) 2 (0.8) 0.030 18 (3.4) 4 (0.9) 0.011
Number of stents implanted 1.2  0.5 — — 1.3  0.6 — — 1.2  0.5 — 0.004*
Total stent length (mm) 32.9  22.0 — — 36.1  24.5 — — 31.3  20.5 — 0.008*
Stent diameter (mm) 3.3  0.2 — — 3.3  0.3 — — 3.3  0.2 — 0.06*
The values are presented as medians (with interquartile ranges), mean SD, or n (%). *p values for diabetes versus nondiabetes.
CABG coronary arterybypassgraft; DESdrug-eluting stent; LADosostiumof the left anterior descending coronary artery; LCXosostiumof the left circumflex coronary artery; LM leftmaindisease;NSTEMI non–ST-segment elevation myocardial infarction.
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959nformation on vital status was obtained through July 15,
007, from the National Population registry of the Korea
ational Statistical Office using unique patient personal
dentification numbers. Follow-up MI, stent thrombosis,
nd TVR were based on clinical diagnoses made by indi-
idual physicians and were centrally adjudicated.
tatistical analysis. Continuous variables were compared
sing Student t test or the Wilcoxon rank sum test, and
ategorical variables were compared using the chi-square
est or Fisher exact test as appropriate. Unadjusted cumu-
ative event rates were estimated by the Kaplan-Meier
ethod and compared by log-rank tests.
Crude and adjusted risks for adverse outcomes were
ompared by univariate and multivariate Cox proportional
azards regression analyses. Multiple regression analyses
sing Cox proportional hazard models were tested with
ABG group as the reference category and with DES
roup as the indicator variable. Variables with p values
0.20 and clinically relevant covariates irrespective of their
tatistical relevance in univariate analyses were candidates
or inclusion in multivariate Cox proportional hazards
odels. The final models were determined by backward
limination.
To reduce the impact of treatment selection bias and
otential confounding factors in an observational study, we
sed weighted Cox proportional hazard models with robust
tandard errors to compare hazard rates of outcomes be-
ween the DES and CABG groups. Weighted Cox’s models
ere constructed using the inverse probability of treatment
eighting (IPTW) approach (15). In this model, weights
ere stabilized by marginal probability for both treatment
roups, respectively. Stabilized weights for patients who
nderwent CABG were the product of the marginal prob-
bility for CABG group and the inverse of (1  propensity
core), and stabilized weights for patients who underwent
ES were the product of the marginal probability for DES
roup and inverse of the propensity score (16).
These treatments effects were evaluated in the total
opulation, and in the diabetic and nondiabetic patients.
nteraction terms in the multivariate Cox model and
eighted Cox model using the IPTW method were used to
est for the statistical significance of 2 treatment effects by
iabetic status on clinical outcomes.
All reported p values were 2-sided, and p values 0.05
ere considered statistically significant. SAS software, ver-
ion 9.1 (SAS Institute, Cary, North Carolina) was used for
ll statistical analyses.
esults
aseline clinical and procedural characteristics. Of the 1,474
atients with unprotected LMCA disease receiving DES
n  784) or CABG (n  690), 507 (34%) had diabetes
ellitus; of the latter, 251 (50%) patients received DES andFigure 1. Cumulative Incidence of Outcomes in Overall Patients
Kaplan-Meier incidence curves of clinical outcomes up to 3 years in the
overall population of patients with unprotected left main coronary artery
lesions who received drug-eluting stents or underwent coronary-artery
bypass grafting. (A) Death. (B) Composite of death, Q-wave myocardial
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96056 (50%) underwent CABG. Of the 967 (66%) nondia-
etic patients, 533 (55%) received DES and 434 (45%)
nderwent CABG.
Clinical, angiographic, and lesional characteristics of
verall, and diabetic and nondiabetic patients, who under-
ent DES and CABG, are shown in Table 1. Compared
ith patients who received DES, those who underwent
ABG had a significantly higher prevalence of coexisting
onditions (old age, peripheral vascular disease, lower ejec-
ion fraction, unstable angina, and higher EuroSCORE)
nd were significantly more likely to have 3-vessel disease
Table 1). Although DES patients had a significantly higher
ncidence of bifurcation lesions than CABG patients, most
f them consisted of isolated and left main plus either ostial
art of left coronary artery system, but complex bifurcation
esions were significantly higher in CABG than DES
roups (Table 1).
utcomes. Figure 1 and Table 2 summarize crude and
djusted outcomes of patients receiving DES versus CABG
n the total population. Overall, the 3-year unadjusted risks of
eath (6.0% vs. 8.1%, p  0.14) and the composite of death,
-wave MI, or stroke (7.3% vs. 9.9%, p  0.19) did not
ignificantly differ between the DES and CABG groups. In
ontrast, the 3-year TVR rate was significantly higher in
atients receiving DES (10.3% vs. 2.8%, p  0.001). After
ultivariable adjustment using standard Cox regression and
PTW, these results were consistent.
In the diabetic population, the 3-year unadjusted risks of
eath (6.4% vs. 8.6%, p 0.37) and the composite of death,
-wave MI, or stroke (8.4% vs. 10.9%, p  0.35) were
Table 2. Kaplan-Meier Cumulative Incidence and Crude and Adjusted HRs
Outcomes
Crude
Mult
HR (95% CI) p Value HR (95% CI)
Overall
Death 0.747 (0.507–1.101) 0.14 1.109 (0.735–1.674)
Death, QMI, or stroke 0.737 (0.518–1.048) 0.089 1.070 (0.735–1.556)
TVR 3.863 (2.344–6.367) 0.0001 5.102 (2.973–8.756)
Diabetic patients
Death 0.744 (0.391–1.417) 0.369 0.793 (0.396–1.586)
Death, QMI, or stroke 0.764 (0.434–1.345) 0.351 0.926 (0.522–1.644)
TVR 5.898 (2.277–15.275) 0.0003 6.213 (2.397–16.106)
Nondiabetic patients
Death 0.755 (0.464–1.229) 0.258 1.05 (0.623–1.768)
Death, QMI, or stroke 0.733 (0.467–1.149) 0.176 1.030 (0.636–1.670)
TVR 3.168 (1.758–5.710) 0.0001 4.273 (2.264–8.066)
*Hazard ratios (HRs) for drug-eluting stents with reference to coronary artery bypass grafting; †adj
sex, insulin-requiring diabetesmellitus, previous congestive heart failure, extent of diseased vessel,
of diseased vessel, EuroSCORE, andbifurcation involvement; adjusted for age, insulin-requiringdiabe
for previous congestive heart failure, cerebrovascular disease, and EuroSCORE; #adjusted for insulin
failure, extent of diseased vessel, and EuroSCORE; ††adjusted for sex, cerebrovascular disease, rena
angioplasty, EuroSCORE, and bifurcation involvement.CI confidence interval; QMI Q-wave myocardial infarction; TVR target-vessel revascularization.imilar in the DES and CABG groups (Fig. 2, Table 2). As
ith the overall population, the 3-year incidence of TVR
as significantly higher in diabetic patients who underwent
ES than in those who underwent CABG (11.2% vs. 2.0%,
 0.001). In the nondiabetic population, the 3-year
nadjusted rates of death (5.8% vs. 7.8%, p  0.19) and the
omposite of death, Q-wave MI, or stroke (6.8% vs. 9.2%,
 0.17) were similar in DES and CABG patients, but the
ate of TVR was significantly higher in DES than in CABG
atients (9.9% vs. 3.2%, p  0.001) (Fig. 3, Table 2). After
djusting for possible confounders using a multivariate Cox
egression model and weighted Cox regression using the
PTW method, these outcomes were consistent, showing
hat DES and CABG carried similar risks of death and the
omposite of death, Q-wave MI, or stroke, and higher risks
f TVR, in the overall, diabetic, and nondiabetic popula-
ions (Table 2).
When we assessed whether the magnitude of the
reatment effects for DES and CABG varied significantly
ccording to diabetes status, we did not observe signifi-
ant interactions between treatment outcomes and the
resence or absence of diabetes after adjustment for covariates
pinteraction  0.90 by multivariate and pinteraction  0.16 by
PTW for death, pinteraction  0.68 by multivariate and
interaction  0.93 by IPTW for the composite of death,
-wave MI, or stroke, and pinteraction  0.23 by multivariate
nd pinteraction  0.92 by IPTW for TVR). Despite large
ifferences in the hazard ratios (HRs) between diabetic and
ondiabetic groups, the overlapping of confidence intervals
ical Outcomes Over 3 Years*
e Adjusted Inverse Probability of Treatment Weighted
Value
Interaction p for
Diabetic Status HR (95% CI) p Value
Interaction p for
Diabetic Status
621† 0.902 0.954 (0.623–1.462) 0.828 0.156
724‡ 0.684 0.962 (0.652–1.419) 0.846 0.934
0001§ 0.233 4.309 (2.278–8.151) 0.0001 0.919
511 0.547 (0.24–1.245) 0.150
793¶ 0.782 (0.377–1.621) 0.509
0002# 7.668 (2.757–21.32) 0.0001
856** 1.004 (0.586–1.718) 0.989
903†† 0.963 (0.586–1.583) 0.882
0001‡‡ 2.943 (1.357–6.384) 0.006
r sex, insulin-requiring diabetes mellitus, extent of diseased vessel, and EuroSCORE; ‡adjusted for
oSCORE; §adjusted for insulin-requiring diabetesmellitus, previous congestive heart failure, extent
llitus, previous congestive heart failure, peripheral vascular disease, and restenotic lesion;¶adjusted
ng diabetesmellitus; **adjusted for sex, cerebrovascular disease, peripheral vascular disease, renal
, extent of diseased vessel, and EuroSCORE; ‡‡adjusted for age, current smoker, previous coronaryof Clin
ivariat
p
0.
0.
0.
0.
0.
0.
0.
0.
0.
usted fo
and Eur
tesme
-requiri
l failure
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961Figure 2. Cumulative Incidence of Outcomes in Diabetic Patients
Kaplan-Meier incidence curves of clinical outcomes up to 3 years in dia-
betic patients with unprotected left main coronary artery lesions who
received drug-eluting stents or underwent coronary artery bypass grafting.
(A) Death. (B) Composite of death, QMI, or stroke. (C) TVR. Abbreviations
as in Figure 1.Figure 3. Cumulative Incidence of Outcomes in Nondiabetic Patients
Kaplan-Meier incidence curves of clinical outcomes up to 3 years in nondia-
betic patients with unprotected left main coronary artery lesions who
received drug-eluting stents or underwent coronary artery bypass grafting.
(A) Death. (B) Composite of death, QMI, or stroke. (C) TVR. Abbreviations
as in Figure 1.
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962CIs) denoted statistical insignificance between the 2 groups
Table 2).
In addition, we directly compared TVR of diabetic with
hose of nondiabetic patients in the DES and CABG
roups, respectively. After adjustment using multivariate
ox model and IPTW, the rates of TVR in diabetic over
ondiabetic patients were similar in both DES (HR: 1.48,
5% CI: 0.81 to 2.71, p  0.21 for multivariate Cox model;
R: 1.14, 95% CI: 0.69 to 1.87, p  0.61 for IPTW) and
ABG groups (HR: 1.75, 95% CI: 0.62 to 4.93, p  0.29
or multivariate Cox model; HR: 1.36, 95% CI: 0.47 to
.92, p  0.57 for IPTW).
iscussion
he major findings of our study were that: 1) among
atients with unprotected LMCA disease, the adjusted risks
f death and the composite of death, Q-wave MI, or stroke
ere similar in patients who received DES or underwent
ABG, whereas the risk of TVR was significantly higher in
ES patients; 2) these findings were consistent in diabetic
nd nondiabetic patients; and 3) diabetes had a minimal
rognostic impact on long-term treatment effects in patients
ho underwent DES or CABG.
Among patients with significant coronary artery disease
ndergoing CABG, periprocedural morbidity and mortal-
ty, long-term mortality, and the rates of repeat revascular-
zation after CABG were found to be higher for diabetic
han for nondiabetic patients (17–19). Diabetic patients
eceiving PCI also showed less favorable long-term survival
nd a higher incidence of restenosis and repeat revascular-
zation than did nondiabetic patients (2,7,9,20). Compared
ith bare-metal stents, DES implantation has markedly
educed the need for repeat revascularization (21,22). A
ecent large meta-analysis of 10 randomized trials (23)
howed that, despite substantial reductions in restenosis
hen DES were used, both in diabetic and nondiabetic
atients, the presence of diabetes was associated with an
ncreased risk of unfavorable clinical outcomes (5,6,22,24).
herefore, diabetic status has been regarded as both a major
isk factor for adverse outcomes and an important clinical
ndicator in the choice of revascularization methods.
Several studies have compared PCI with CABG for
ultivessel disease treatment in diabetic patients. In dia-
etic subgroups from the ARTS (Arterial Revascularization
herapies Study) undergoing multivessel stenting using
are-metal stents and CABG, the incidence of death, MI,
r stroke at 1 and 5 years did not differ between groups, but
here was a higher incidence of repeat revascularization after
tenting than after CABG (4,20). Even in the ARTS II
rial, which compared DES with CABG, there were no
ignificant differences in mortality, MI, and stroke, but righer rates of revascularization were observed after DES
mplantation (25). Although the BARI 2D (Bypass Angio-
lasty Revascularization Investigation 2 Diabetes) trial
ould not compare PCI with CABG directly, patients who
nderwent CABG, but not PCI (DES, 35%), had signifi-
antly fewer major adverse cardiac events, as compared with
atients who underwent optimal medical therapy (26).
Data comparing PCI and CABG in diabetic subsets with
nprotected LMCA disease are, however, limited. Two
ngoing large-scale randomized controlled studies compar-
ng DES with CABG in patients with diabetes exclude
atients with LMCA disease (27,28). A diabetic subgroup
nalysis of the SYNTAX (SYNergy between percutaneous
oronary intervention with TAXus and cardiac surgery) trial
howed similar hard end points, including death, MI, or
troke, but higher repeat revascularization rates in patients
ith 3-vessel or LMCA disease (29). These results were
imilar to ours. We also found that treatment effects of the
primary interventions for patients with unprotected
MCA disease were consistent in diabetic and nondiabetic
atients, without significant interactions. Similar trends
ere seen in previous randomized or registry studies com-
aring PCI with CABG in diabetic patients with multives-
el coronary artery disease (20,22,25,30,31).
tudy limitations. Our study had several limitations. De-
pite rigorous adjustment using standard and weighted Cox
egression employing IPTW, it was an inherent limitation
or the choice of treatment modality, which was based on
he physician’s or patient’s preference, and otherwise un-
easured confounders or hidden bias may be present.
econd, we may have inadequate statistical power to detect
mall outcome differences between the 2 revascularization
trategies in diabetic and nondiabetic subgroups. Third,
ecause our results are mainly derived from subgroup
nalyses, they should be regarded as exploratory in nature,
nd hypothesis-generating. Therefore, our findings should
e confirmed or rebutted by large, prospective randomized
linical studies.
onclusions
hen the outcomes of 2 primary interventions (DES vs.
ABG) for unprotected LMCA disease were compared,
he adjusted risks of death and the composite of death,
-wave MI, or stroke were similar, but the risk of TVR was
ignificantly higher in DES patients. These findings were
onsistent in diabetic and nondiabetic patients, without
ignificant interactions. Additional large clinical trials are
arranted to evaluate the prognostic or clinical impact of
iabetes in patients with multivessel coronary artery disease
equiring revascularization procedures.
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